Design and Evaluation of Nanosuspension for improved Psoriasis Treatment

Psoriasis is a chronic, immune-mediated skin disease marked by excessive keratinocyte proliferation, resulting in scaly, inflamed plaques. Topical corticosteroids are widely used but are limited by poor solubility, low skin permeability, and systemic side effects. This study aimed to develop and optimize a nanosuspension of Clobetasol-17-propionate for improved topical delivery. Nanosuspensions were prepared using the nanoprecipitation method and optimized via Box—Behnken design, with β-cyclodextrin (β-CD), sodium lauryl sulfate (SLS), and sonication time as independent variables. The optimized formulation (T7) demonstrated a particle size of 371.6nm, entrapment efficiency of 90.00%, and zeta potential of –34.21mV, indicating good physical stability. FTIR and DSC confirmed drug—excipient compatibility, while FE-SEM revealed spherical morphology. The formulation showed suitable pH (5.5), viscosity (856 Cps), and high drug content (96.00%). in-vitro diffusion studies confirmed controlled drug release, with 96.08% cumulative release in 240minutes. Stability studies over six months showed no significant changes in particle size or drug entrapment. the results suggest that the nanosuspension effectively enhances skin retention and controlled release of Clobetasol-17-propionate, making it a promising approach for the topical treatment of psoriasis.